Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Optic Nerve Sheath Meningioma Treatment & Management

  • Author: Mitchell V Gossman, MD; Chief Editor: Hampton Roy, Sr, MD  more...
 
Updated: May 18, 2016
 

Medical Care

Many believe that patients with optic nerve sheath meningioma (ONSM) can be observed if there is no evidence of intracranial extension and if there is mild or no vision loss or, in some cases, stable degrees of vision loss.[13]

Radiologic findings help diagnose most cases; therefore, biopsy is unnecessary. Biopsy should be reserved for only rare cases with ambiguous neuroimaging findings because the effects on vision can be catastrophic.

Radiotherapy

Treatment with primary radiation or radiation following surgical removal has been associated with a better chance of visual improvement.[14, 15, 16]

Conventional radiation therapy is beneficial for patients with recurrent (or incompletely resected) benign meningiomas, and it is recommended for patients with aggressive and malignant meningiomas. Patients with meningiomas are good candidates for radiotherapy because the tumors are extra-axial and are visualized easily on CT scan or MRI. Stereotactic radiation and interstitial brachytherapy are useful in some refractory or recurrent meningiomas.

In the largest, most comprehensive review of patients with meningiomas from 1962-1980 by Mirimanoff et al, only 80 patients out of 225 had residual tumor after debulking.[17] This study suggests that the recurrence rate for patients with full resection of tumor is about 10%, whereas patients with subtotal resection had a recurrence rate of 55% at 10 years and 91% at 15 years.

In another study by Barbaro et al, patients with subtotal resection of benign meningiomas were divided into 2 groups; one group received postoperative radiotherapy, and the other group was only observed.[18] The rate of tumor progression was 60% for the latter group and 32% for the former group. In addition, the time to progression was twice as long for patients who had received radiotherapy. The improved survival rate was associated with higher radiation doses; 93% survival rate for patients having received 52 Gy versus 65% for patients treated with smaller doses.

In a study by Goldsmith et al, the 5-year survival rate was 58% for patients with malignant meningiomas who had received additional radiotherapy. This rate was significantly higher than the survival rate of patients who had only surgery. In this group, only 3.6% had serious complications (eg, blindness, brain necrosis). In another review by Glaholm et al, the 10-year survival rate was 46% for patients who had received radiotherapy alone for treatment of unresectable meningiomas.[19]

One proposed protocol to minimize adverse effects is to deliver fractionated external radiation of 1.8 Gy per day for a total of 54 Gy. For superficial tumors, radiation with a 4-6 MV accelerator or a Cobalt 60 machine is preferred because these parameters spare skin lesions and allow a rapid build-up of radiation dose.

Radiosurgery can be delivered with either a gamma knife or a modified linear accelerator. The gamma knife can deliver multiple small fields with relative ease; therefore, it conforms well to uneven masses. The use of linear accelerators for radiosurgery and stereotactic radiotherapy has resulted in an improved outcome from radiation. In a series of 56 skull base meningiomas by Black, 95% of them were controlled (ie, showed no growth) over a 4-year period.[20]

Chemotherapy

Chemotherapy is reserved for patients with unresectable, recurrent, or previously irradiated meningiomas. Combination treatment with 5-fluroouracil, folate, and levamisole, or a combination of intra-arterial cisplatin with intravenous doxorubicin, may be beneficial. Other proposed combinations include Adriamycin and dacarbazine or ifosfamide and mesna. Adriamycin is an antibiotic that causes DNA damage. Dacarbazine (DTIC) is an alkalizing agent that inhibits DNA synthesis for a total of 1 year, if the tumor responds, or indefinitely until a response occurs.

In a pilot study with mifepristone by Greenberg et al, a marginal response was seen in a small group of patients (6 out of 24 patients).[21] Another study by Grunberg et al confirmed benefit for a majority of 14 patients.[22]

Interferon alpha is the most frequently advocated immunotherapy and is generally well tolerated. It has been shown to have a growth inhibitory effect in vitro, and isolated reports have indicated a stabilizing response in unresectable benign meningiomas.

Next

Surgical Care

The management scheme below has been proposed.

In the absence of visual impairment, follow up with visual function testing, including pupil testing, color vision testing, and perimetry, every 6-12 months and obtain an MRI every 1-2 years.

If visual acuity or the visual field deteriorates, it may be beneficial to treat the patient with radiation to the orbit.

If the eye is blind and the tumor is confined to the orbit, observe the patient. (In some cases, if the eye is completely blind, some advocate surgically resecting the ONSM; the globe sometimes can be left behind.)

If the eye is blind and intracranial extension is present, excise the tumor and the nerve. Possible complications of surgery include visual impairment, postoperative bleeding, and cerebrospinal fluid leakage.

Preoperative evaluation of patients with anterior basal meningiomas includes a careful visual testing and a complete neuro-ophthalmological evaluation. Endocrine testing is important, as pituitary insufficiency has been reported to occur in 22% of patients with anterior skull base meningiomas. MRI angiography may be helpful in establishing the relationship of the tumor to its vascular supply. Three-dimensional scanning is becoming increasingly popular because it can be taken into the operating room and linked to the operative instruments. Surgery remains the mainstay of meningioma management.

For any skull base surgery, the procedure can be divided into 3 steps, as follows:

  • The first step consists of providing wide exposure of the involved area. Avoid brain retraction, and interrupt the blood supply to the tumor early in the procedure to reduce intraoperative blood loss. Blood supply to the tuberculum sella is typically from posterior ethmoidal arteries with possible additional blood supply from the ipsilateral anterior cerebral artery and the anterior communicating artery. These tumors tend to displace the optic chiasm posteriorly and the optic nerves laterally and superiorly. Removal of the posterior portion of the tumor usually is relatively easy, as the posterior elements are easy to locate and usually are spared from tumor invasion.
  • The second step of the surgery consists of debulking the central portion of the tumor after dissecting its thin arachnoidal membrane capsule. Remove the involved dura and the involved bony structures. It is important to assume that the tumor is present in all areas of hyperostosis.
  • The third step is reconstructive. To minimize the risk of infection and spinal fluid leakage, separate the intracranial contents from the paranasal sinuses, the mastoid air cells, and the airway structures. A unilateral approach may be used for tuberculum sella meningiomas, including a supraorbital osteotomy, or, alternatively, make a bicoronal incision to allow access to a large pericranial flap. Once the bone flap is removed, the frontal dura and the periorbital area can be visualized. Detaching the tumor from the skull is the first step to devascularize the tumor. Complete excision usually is achieved in 97% of cases of meningiomas of the convexity. Recurrence is strongly associated with the degree of surgical debulking. Only 30% of patients with skull base meningiomas had full resection.
Previous
Next

Consultations

In cases of optic nerve sheath meningioma (ONSM), a team approach involving ophthalmologists, neurologists, neurosurgeons, radiation therapists, and radiologists is most beneficial.

Previous
 
 
Contributor Information and Disclosures
Author

Mitchell V Gossman, MD Partner and Vice President, Eye Surgeons and Physicians, PA; Medical Director, Central Minnesota Surgical Center; Clinical Associate Professor, University of Minnesota Medical School

Mitchell V Gossman, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Ophthalmology, American Medical Association, American Society of Cataract and Refractive Surgery, Minnesota Medical Association, North American Neuro-Ophthalmology Society, Phi Beta Kappa

Disclosure: Nothing to disclose.

Coauthor(s)

Sally B Zachariah, MD Associate Professor, Department of Neurology, University of South Florida College of Medicine; Director, Department of Neurology, Division of Strokes, Veteran Affairs Medical Center of Bay Pines

Sally B Zachariah, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Society of Neuroimaging

Disclosure: Partner received none from none for none.

Specialty Editor Board

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy, Sr, MD Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy, Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

Andrew W Lawton, MD Neuro-Ophthalmology, Ochsner Health Services

Andrew W Lawton, MD is a member of the following medical societies: American Academy of Ophthalmology, Arkansas Medical Society, Southern Medical Association

Disclosure: Nothing to disclose.

Acknowledgements

Suzan Khoromi, MD Fellow, Pain and Neurosensory Mechanisms Branch, National Institute of Dental and Cranial Research, National Institutes of Health

Suzan Khoromi, MD is a member of the following medical societies: American Academy of Neurology, American Pain Society, and International Association for the Study of Pain

Disclosure: Nothing to disclose.

Brian R Younge, MD Professor of Ophthalmology, Mayo Clinic School of Medicine

Brian R Younge, MD is a member of the following medical societies: American Medical Association, American Ophthalmological Society, and North American Neuro-Ophthalmology Society

Disclosure: Nothing to disclose.

References
  1. Cushing H, Eisenhardt L. Meningiomas: their classification, regional behaviour, life history, and surgical end results. Springfield, Ill: Charles Thomas; 1938.

  2. Coke CC, Corn BW, Werner-Wasik M, Xie Y, Curran WJ Jr. Atypical and malignant meningiomas: an outcome report of seventeen cases. J Neurooncol. 1998 Aug. 39(1):65-70. [Medline].

  3. Menon G, Nair S, Sudhir J, Rao BR, Mathew A, Bahuleyan B. Childhood and adolescent meningiomas: a report of 38 cases and review of literature. Acta Neurochir (Wien). 2009 Mar. 151(3):239-44; discussion 244. [Medline].

  4. Harold Lee HB, Garrity JA, Cameron JD, Strianese D, Bonavolontà G, Patrinely JR. Primary optic nerve sheath meningioma in children. Surv Ophthalmol. 2008 Nov-Dec. 53(6):543-58. [Medline].

  5. Sheikh BY, Siqueira E, Dayel F. Meningioma in children: a report of nine cases and a review of the literature. Surg Neurol. 1996 Apr. 45(4):328-35. [Medline].

  6. Pompili A, Derome PJ, Visot A, Guiot G. Hyperostosing meningiomas of the sphenoid ridge--clinical features, surgical therapy, and long-term observations: review of 49 cases. Surg Neurol. 1982 Jun. 17(6):411-6. [Medline].

  7. Boschetti NV, Smith JL, Osher RH, Gass JD, Norton EW. Fluorescein angiography of optociliary shunt vessels. J Clin Neuroophthalmol. 1981 Mar. 1(1):9-30. [Medline].

  8. Sibony PA, Krauss HR, Kennerdell JS, Maroon JC, Slamovits TL. Optic nerve sheath meningiomas. Clinical manifestations. Ophthalmology. 1984 Nov. 91(11):1313-26. [Medline].

  9. Chacko JG, Schatz NJ, Glaser JS. Delayed optic nerve complications after proton beam irradiation. Ann Ophthalmol (Skokie). 2008 Fall-Winter. 40(3-4):166-70. [Medline].

  10. McCutcheon IE. The biology of meningiomas. J Neurooncol. 1996 Sep. 29(3):207-16. [Medline].

  11. Ing EB, Garrity JA, Cross SA, Ebersold MJ. Sarcoid masquerading as optic nerve sheath meningioma. Mayo Clin Proc. 1997 Jan. 72(1):38-43. [Medline].

  12. [Guideline] Zimmerman RD, Seidenwurm DJ, Davis PC, Brunberg JA, De La Paz RL, Dormont PD, et al. Orbits, vision, and visual loss. [online publication]. Reston (VA): American College of Radiology (ACR); 2006. [Full Text].

  13. Miller NR. New concepts in the diagnosis and management of optic nerve sheath meningioma. J Neuroophthalmol. 2006 Sep. 26(3):200-8. [Medline].

  14. Milker-Zabel S, Huber P, Schlegel W, Debus J, Zabel-du Bois A. Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neurooncol. 2009 Apr 1. [Medline].

  15. Arvold ND, Lessell S, Bussiere M, Beaudette K, Rizzo JF, Loeffler JS, et al. Visual Outcome and Tumor Control After Conformal Radiotherapy for Patients With Optic Nerve Sheath Meningioma. Int J Radiat Oncol Biol Phys. 2009 Apr 28. [Medline].

  16. Smee RI, Schneider M, Williams JR. Optic nerve sheath meningiomas--non-surgical treatment. Clin Oncol (R Coll Radiol). 2009 Feb. 21(1):8-13. [Medline].

  17. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985 Jan. 62(1):18-24. [Medline].

  18. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB, Wara WM. Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery. 1987 Apr. 20(4):525-8. [Medline].

  19. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys. 1990 Apr. 18(4):755-61. [Medline].

  20. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci. 1997 Nov. 24(4):302-6. [Medline].

  21. Greenberg HS. Meningiomas. Gilman S, Goldstein GW, Waxman SG. Neurobase. 1st ed. Arbor Publishing: San Diego; 1998.

  22. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991 Jun. 74(6):861-6. [Medline].

  23. De Monte F. Current management of meningiomas. Oncology (Williston Park). 1995 Jan. 9(1):83-91, 96; discussion 96, 99-101. [Medline].

  24. Black P, Kathiresan S, Chung W. Meningioma surgery in the elderly: a case-control study assessing morbidity and mortality. Acta Neurochir (Wien). 1998. 140(10):1013-6; discussion 1016-7. [Medline].

  25. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ. Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys. 1996 Mar 1. 34(4):817-22. [Medline].

  26. Akeyson EW, McCutcheon IE. Management of benign and aggressive intracranial meningiomas. Oncology (Williston Park). 1996 May. 10(5):747-56; discussion 756-9. [Medline].

  27. Donnell MS, Meyer GA, Donegan WL. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg. 1979 Apr. 50(4):499-502. [Medline].

  28. Finn JE, Mount LA. Meningiomas of the tuberculum sellae and planum sphenoidale. A review of 83 cases. Arch Ophthalmol. 1974 Jul. 92(1):23-7. [Medline].

  29. Firsching RP, Fischer A, Peters R, Thun F, Klug N. Growth rate of incidental meningiomas. J Neurosurg. 1990 Oct. 73(4):545-7. [Medline].

  30. Kennerdell JS, Maroon JC, Malton M, Warren FA. The management of optic nerve sheath meningiomas. Am J Ophthalmol. 1988 Oct 15. 106(4):450-7. [Medline].

  31. Kinjo T, Mukawa J, Koga H, Shingaki T. An extensive cranial base meningioma extending bilaterally into Meckel's cave: case report. Neurosurgery. 1997 Mar. 40(3):615-7; discussion 617-8. [Medline].

  32. Kyritsis AP. Chemotherapy for meningiomas. J Neurooncol. 1996 Sep. 29(3):269-72. [Medline].

  33. Langford LA. Pathology of meningiomas. J Neurooncol. 1996 Sep. 29(3):217-21. [Medline].

  34. Lee AG, Woo SY, Miller NR, Safran AB, Grant WH, Butler EB. Improvement in visual function in an eye with a presumed optic nerve sheath meningioma after treatment with three-dimensional conformal radiation therapy. J Neuroophthalmol. 1996 Dec. 16(4):247-51. [Medline].

  35. Lloyd GA. Primary orbital meningioma: a review of 41 patients investigated radiologically. Clin Radiol. 1982 Mar. 33(2):181-7. [Medline].

  36. Mafee MF, Goodwin J, Dorodi S. Optic nerve sheath meningiomas. Role of MR imaging. Radiol Clin North Am. 1999 Jan. 37(1):37-58, ix. [Medline].

  37. Maor MH. Radiotherapy for meningiomas. J Neurooncol. 1996 Sep. 29(3):261-7. [Medline].

  38. Maroon JC, Kennerdell JS. Optic nerve sheath meningioma. Arch Neurol. 1981 May. 38(5):326. [Medline].

  39. Nakagawa H, Lusins JO. Biplane computed tomography of intracranial meningiomas with extracranial extension. J Comput Assist Tomogr. 1980 Aug. 4(4):478-83. [Medline].

  40. Russel DS, Rubinstein LJ. Russell and Rubinstein's Pathology of Tumors of the Nervous System. Bigner DD, McLendon RE, Bruner JM, eds. Hodder Headline Group. Vol. 1:1998.

  41. Schlehofer B, Blettner M, Wahrendorf J. Association between brain tumors and menopausal status. J Natl Cancer Inst. 1992 Sep 2. 84(17):1346-9. [Medline].

  42. Zimmerman RA. Imaging of intrasellar, suprasellar, and parasellar tumors. Semin Roentgenol. 1990 Apr. 25(2):174-97. [Medline].

 
Previous
Next
 
Meningioma of the orbit. Axial sequence on T1-weighted MRI with gadolinium that shows enhancing lesion of the orbit causing proptosis and en plaque invagination laterally around the temporal pole and medially above the ethmoid sinus.
Meningioma of the optic nerve sheath. Coronal section of T1-weighted MRI of the orbits that shows a left orbital mass lesion occupying most of the orbital lumen, diffusely enhancing with gadolinium.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.